On August 12, a large number of pharmaceutical companies issued important announcements, involving shareholder reduction, cash dividends, semi-annual report release, product review, executive resignation, etc.
, which are full of highlights! Let's take a brief look at it together
.
【Product review】
【Product review】
On August 12, China National Pharmaceutical announced that the atropine sulfate injection of Tianfang Co.
, Ltd.
, a wholly-owned subsidiary of the company, has been evaluated by the State Drug Administration for the consistency of quality and efficacy of generic drugs
.
This medicine is mainly suitable for all kinds of visceral colic
.
As of the disclosure date of this announcement, Tianfang Co.
, Ltd.
has invested approximately RMB 3.
839 million (unaudited) in this drug project
.
【Semi-annual report】
【Semi-annual report】
Kasai Bio disclosed its 2022 semi-annual report.
In the first half of the year, it achieved revenue of 1.
289 billion yuan, a year-on-year increase of 13.
53%; net profit attributable to the parent was 336.
5 million yuan, a year-on-year increase of 7.
71%; net profit attributable to the parent after deduction was 335.
6 million yuan, a year-on-year increase 14.
83%
.
Kasai Bio is an enterprise engaged in the research and development, production and sales of new bio-based materials based on synthetic biology and other disciplines using bio-manufacturing technology
.
Dirui Medical's 2022 semi-annual report shows that the company achieved operating income of 515 million yuan in the first half of the year, an increase of 23.
27% over the same period last year; net profit attributable to shareholders of listed companies was 133 million yuan, an increase of 20.
65% over the same period last year
.
The company is an enterprise that has been deeply engaged in the field of in vitro diagnostics and has long adhered to the balanced development of reagents and instruments
.
Jinhe Biological achieved operating income of 1.
125 billion yuan in the first half of the year, a year-on-year increase of 17.
11%; net profit attributable to shareholders of listed companies was 86.
6919 million yuan, a year-on-year decrease of 15.
27%
.
Jinhe Bio is an enterprise specializing in the production, sales, R&D and service of animal health products.
The products cover veterinary chemicals, veterinary vaccines, animal nutrition, corn starch and industrial sewage treatment services
.
Yiqiao Shenzhou announced that the company's operating income in the first half of 2022 will be 299 million yuan, a year-on-year decrease of 52.
84%; net profit attributable to the parent is 192 million yuan, a year-on-year decrease of 56.
58%; basic earnings per share are 1.
95 yuan
.
The company is a biotechnology company engaged in the research and development, production, sales and provision of technical services of biological reagents.
Its main business includes recombinant proteins, antibodies, genes and culture media and other products, as well as the development of recombinant proteins and antibodies, and bioanalytical testing services
.
【Cash Dividend】
【Cash Dividend】
Shanghai Pharmaceuticals announced the 2021 annual equity distribution implementation plan: This profit distribution is based on the company's total share capital of 223 million shares before the implementation of the plan, and a cash dividend of 0.
070 yuan (tax included) per share will be distributed, with a total cash dividend of 15.
616 million yuan
.
【Shareholders' shareholding reduction】
【Shareholders' shareholding reduction】
Aojin Medical announced that the company received a notification letter from BioVeda China RMB Investment Limited, a shareholder holding more than 5% of the shares, on August 11, 2022.
BioVeda China RMB Investment Limited During the day, a total of about 1.
7328 million shares of the company were reduced through block transactions and centralized bidding, and the number of shares reduced accounted for 1.
2996% of the company's total share capital
.
【Corporate Change】
【Corporate Change】
According to the announcement of Unnamed Biology, the company held the twenty-eighth meeting of the fourth board of directors on August 9, 2022 to consider and approve the "Proposal on the Adjustment of the Work of the Board of Directors", and to elect Mr.
Yue Jialin as the company's chairman
.
【Resign】
【Resign】
CTI announced that the board of directors of the company recently received a written resignation report submitted by Mr.
Cheng Hong, an independent director
.
Mr.
Cheng Hong has served as an independent director for six consecutive years
.
According to the regulations, Mr.
Cheng Hong applied for his resignation as an independent director of the company and a member of a special committee of the board of directors, and will no longer hold any positions in the company after the resignation takes effect
.
